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The role of inflammation in Alzheimer’s disease (AD) and other cognitive disorders is
unclear. In a well-defined mono-center population, we measured cytokines and chemokines
in paired serum and cerebrospinal fluid (CSF) samples.
Methods
Consecutive patients with AD (n = 30), stable mild cognitive impairment (SMCI, n = 11),
other dementias (n = 11), and healthy controls (n = 18) were included. None of the subjects
was treated with glucocorticoids, cholinesterase inhibitors, or non-steroidal anti-inflamma-
tory drugs. Serum and CSF concentrations of interleukin-6 (IL-6), IL-8, IL-12/23 p40, IL-15,
IL-16, vascular endothelial growth factor-A (VEGF-A), and three chemokines were mea-
sured using a multiplex panel.
Results
After correction for multiple comparisons, only CSF IL-12/23 p40 concentration differed sig-
nificantly between the total patient group (n = 52) and controls (n = 18; p = 0.002). Further
analyses showed that CSF IL-12/23 p40 concentration was decreased in all patient sub-
groups (AD, other dementias, and SMCI) compared to healthy controls (p < 0.01, p < 0.05,
and p < 0.05, respectively). In the total study population (n = 70), CSF IL-12/23 p40 concen-
trations correlated positively with CSF concentrations of β-amyloid1-42 (Aβ1–42) and phos-
phorylated tau protein (P-tau) whereas in AD patients (n = 30), CSF IL-12/23 p40 only
correlated positively with CSF P-Tau (r = 0.46, p = 0.01).
Conclusions
Most cytokines and chemokines were similar in patients and controls, but CSF IL-12/23 sub-
unit p40 concentration was decreased in patients with cognitive impairment, and correlated
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with markers of AD disease status. Further studies are needed to evaluate the role of CSF
IL-12/23 p40 in other dementias and SMCI.
Introduction
Cytokines are small proteins that can exert autocrine, paracrine, and endocrine actions [1].
Although cytokines may have specific functions, most functions can be stimulated also by
other cytokines [1]. Some cytokines, like interleukin-6 (IL-6), are proinflammatory whereas
other cytokines regulate the proinflammatory cytokine response [1]. The major function of
chemokines is to induce migration of inflammatory cells [1].
In Alzheimer’s disease (AD), amyloid-β (Aβ) deposits and neurofibrillary tangles provide
stimuli for inflammation, and activated immune cells and microglia are accumulated in the
AD brain [2]. The neuroinflammation in AD might not only be a consequence of Aβ mismeta-
bolism, but immune system-mediated actions could also drive AD pathogenesis [2]. Although
overexpression of IL-6 or IL-1β produced inconclusive results in terms of amyloid load and
tau accumulation in mouse AD models [3, 4], two recent studies in mice showed that IL-12
and IL-23 was upregulated in the senescent/AD brain, and experimentally induced inactiva-
tion of the common IL-12 and IL-23 subunit p40 reduced amyloid load and improved cogni-
tive functions [5, 6]. Furthermore, administration of anti-inflammatory agents such as non-
steroidal anti-inflammatory drugs (NSAIDs) reduced amyloid plaque load and microglial acti-
vation in animal models [7]. Human observational studies suggest that especially long-term
use of anti-inflammatory drugs could reduce the risk of AD [8, 9], but randomized controlled
trials have so far showed no clear effect on AD progression [10, 11].
In a meta-analysis of cytokines in AD, circulating (blood) concentrations of tumor necrosis
factor (TNF)-α, transforming growth factor (TGF)-β, IL-1β, IL-6, IL-12 and IL-18 were
increased in AD patients whereas in CSF, only TGF-β was elevated [12]. Dementing disorders
other than AD have different underlying pathogenesis and clinical presentation, but changes
in inflammatory markers and neuroinflammation can be observed also in other dementias
[13, 14]. In another meta-analysis, higher peripheral concentrations of C-reactive protein
(CRP) and IL-6 were associated with an increased risk of all-cause dementia whereas the asso-
ciation with risk of AD alone was weak [15]. Furthermore, although the mechanisms underly-
ing neuroinflammation might differ depending on the cognitive disorder studied, some
changes might also be overlapping. For instance, vascular pathology in the brain, which have
been associated with inflammatory markers [15], can frequently be seen at postmortem exami-
nation in several neurodegenerative diseases [16].
Although inflammation is involved in cognitive decline, the nature of this involvement is
still not fully clear. In a well-characterized mono-center cohort of patients with cognitive
impairment and matched healthy controls, we determined serum and CSF concentrations of
cytokines and chemokines using a multiplex panel. We also studied whether there were associ-
ations with CSF levels of AD biomarkers.
Materials and methods
Study participants
The study participants as well as AD CSF biomarkers have been reported previously [17]. The
study consisted of consecutively recruited Caucasian patients admitted by their general practi-
tioner for evaluation of cognitive impairment to a memory clinic in Falko¨ping, Sweden. The
CSF IL-12/23 p40 in cognitive impairment
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participants were recruited by a single specialized physician (P.J.) 2000–2008. Inclusion crite-
ria, beside being referred to Falko¨ping Hospital for evaluation of suspected dementia, were age
65–80 years, body mass index (BMI) 20–26 kg/m2, and waist:hip ratio 0.65–0.90 in women
and 0.70–0.95 in men. Exclusion criteria were serum creatinine > 175 mmol/L, diabetes melli-
tus, previous myocardial infarction, malignancy including brain tumor, subdural hematoma,
ongoing alcohol abuse and previous or present medication with glucocorticoids or acetylcho-
line esterase inhibitors.
Control subjects were recruited contemporaneously from the same geographical area
among spouses of the included patients and by advertisements in local newspapers. The con-
trols had no subjective symptoms of cognitive dysfunction but otherwise, inclusion and exclu-
sion criteria were similar as those in the patients. Totally, 60 patients and 20 healthy controls
were recruited. However, in this analysis, patients treated with non-steroidal anti-inflamma-
tory drugs (NSAIDs) were excluded. Therefore, 52 patients (29 men and 23 women) and 18
healthy controls (10 men and 8 women) were included in the present study.
The presence or absence of dementia was diagnosed according to the Diagnostic and Statisti-
cal Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria. Patients with dementia were
classified as suffering of Alzheimer’s disease (AD) [18], vascular dementia (VaD) according to
the requirements by NINDS-AIREN [19] or the guidelines by Erkinjuntti et al. for the subcorti-
cal type of VaD [20], and dementia with Lewy bodies (DLB) as described previously [17].
All diagnoses were assessed by an independent specialized physician at a university hospital
that was blinded to the results of CSF biomarkers, otherwise the specialist physician had access
to all clinical data [17]. Mild cognitive impairment (MCI) was diagnosed in patients with cog-
nitive impairment that did not fulfil the criteria for dementia [21]. Patients with MCI were fol-
lowed at least annually for a median of 3 (range 1–7) years to evaluate whether they later
developed dementia. During the follow-up visits, 11 patients remained stable in MCI (SMCI).
Others progressed, during the follow-up period, to dementia and were diagnosed with AD
(n = 6) or VaD (n = 3). MCI patients diagnosed with AD on follow-up visits did not differ in
CSF concentrations of the AD biomarkers β-amyloid1-42 (Aβ1–42), total-tau (T-tau) or phos-
phorylated tau protein (P-tau) from patients with established AD at baseline (data not shown).
Totally, the study population consisted of AD dementia or MCI diagnosed with AD dementia
upon follow-up (n = 30), other dementias (n = 11), SMCI (n = 11), and healthy controls
(n = 18). The distribution of diagnoses in the other dementia group were VaD or MCI diag-
nosed with VaD upon follow-up (n = 7) and DLB (n = 4).
Ethical considerations
The study was approved by the ethical committee at University of Gothenburg (ethical
approval number 496–99, T 452–05). The specialist physician (P.J.) gave written information
of the study and explained the study protocol to the controls as well as to the patients and care-
taker if available. All participants provided both oral and written informed consent. A next of
kin, caretaker or guardian consented on behalf of patients if the capacity to consent was com-
promised. However, in all cases, the patient’s own opinion was asked and considered, and the
patient was recruited in the study only when he or she agreed with this. The ethical committee
approved this informed consent procedure. The study was conducted according to the princi-
ples in the Declaration of Helsinki.
Cognitive and physical examination
Before the test day, a mini-mental state examination (MMSE) [22] was performed. On the test
day morning with the patients in the fasted state, before lumbar puncture was performed,
CSF IL-12/23 p40 in cognitive impairment
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body weight was measured to the nearest 0.1 kg, body height was measured barefoot to the
nearest 0.01 m, and body mass index (BMI) was calculated as the weight in kilograms divided
by the height in meters squared. Waist circumference and hip girth was measured as described
previously [17].
CSF Sampling
All CSF samples were collected by lumbar puncture in the L3/L4 or L4/L5 interspace at the
standardized time point 8.30–9.00 am. The first 12 mL of CSF was collected in a polypropylene
tube and immediately transported to the local laboratory for centrifugation at 2.000g at +4˚C
for 10 minutes. The supernatant was pipetted off, gently mixed to avoid possible gradient
effects, and aliquoted in polypropylene tubes that were stored at -80˚C pending biochemical
analyses, without being thawed and re-frozen.
Blood samples
Blood samples were drawn in the morning in the fasted state and serum was prepared by cen-
trifugation after coagulation at room temperature for 15–30 min, aliquoted and stored in cryo-
tubes at -80˚C pending biochemical analyses, without being thawed and re-frozen.
Biochemical procedures
All biochemical analyses were performed with the analyst blinded to the clinical diagnoses and
other clinical information. All CSF analyses were performed at the Clinical Neurochemistry
Laboratory in Mo¨lndal, Sweden, by experienced laboratory technicians. All analyses were
done at one occasion, using the same batch of reagents. CSF Aβ1–42 concentrations were deter-
mined using the INNOTEST1 ELISA assay technology (Innogenetics, Ghent, Belgium) [23].
The axonal damage marker CSF T-tau and CSF concentrations of tau phosphorylated at threo-
nine 181 (P-tau181) were measured using INNOTEST1 ELISA assays [24, 25].
Cytokines and chemokines were measured using the V-PLEX Human Cytokine 30-Plex
Panel Kit according to instructions from the manufacturer (Cat#: K15054G, Meso Scale Diag-
nostics, Rockville, Maryland). IL-6, IL-8, IL-12/23 p40, IL-15, IL-16, vascular endothelial
growth factor-A (VEGF-A), interferon-γ-inducible protein-10 (IP-10), monocyte chemotactic
protein-1 (MCP-1), and macrophage inflammatory protein-1β (MIP-1β) were present at con-
centrations within the dynamic range of the assay in both serum and CSF, whilst IL-1α, IL-1β,
IL-2, IL-4, IL-5, IL-7, IL-10, IL-12p70, IL-13, IL-17, tumor necrosis factor (TNF)-α, TNF-β,
granulocyte macrophage-colony stimulating factor (GM-CSF), interferon-γ (IFN-γ), eotaxin,
eotaxin-3, MCP-4, macrophage derived chemoattractant (MDC), MIP-1α, and thymus and
activation-regulated chemokine (TARC) were below the limit of detection in serum and/or
CSF and are therefore not reported. In terms of IL-12/23 p40, the relative error for the back
calculated concentrations of the calibrator curve, using data from the two runs needed to com-
plete the CSF samples, were below 12% for all calibrator points. The range spanned by the cali-
brators was 0.69–2840 pg/mL, and all CSF IL-12/23 p40 samples had a higher signal than the
lowest calibrator.
Statistical analyses
The descriptive statistical results are given as the median (25th-75th percentile) if not other-
wise stated. For continuous variables, between-group differences were assessed using the non-
parametric Kruskal-Wallis test for comparisons between multiple groups, followed by the
Mann-Whitney U test for pair-wise comparisons. Chi-square tests were used for group
CSF IL-12/23 p40 in cognitive impairment
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comparisons of categorical variables. Correlations were sought using the Spearman rank order
correlation test. Significance was obtained if the two-tailed p-value was 0.05.
Results
Serum and CSF concentrations of cytokines and chemokines
Cytokine and chemokine concentrations in serum and CSF are given in Table 1. In serum as
well as in CSF, the concentrations of the cytokines IL-6, IL-8 and IL-15, the cytokine/growth fac-
tor VEGF-A, and the chemokines IP-10 and MIP-1β were similar in the total group of patients
(n = 52) compared to the controls (n = 18) (Table 1). In the patient group, serum concentrations
of IL-16 and MCP-1 were decreased (p = 0.004 and p = 0.03 vs. controls, respectively) while CSF
concentrations of IL-16 and MCP-1 were unchanged. However, the reductions in serum IL-16
and MCP-1 concentrations lost statistical significance after adjustment for multiple comparisons
[18 cytokine levels were analyzed (9 in serum and 9 in CSF); Bonferroni correction: p-value of
0.05 divided by 18 ( 0.0028) was considered significant]. Serum IL-12/23 p40 was unaffected
whereas CSF IL-12/23 p40 was decreased in patients compared to controls (p = 0.0020), and this
difference remained statistically significant also after correction for multiple comparisons. Fur-
ther analyses were therefore only performed in terms of IL-12/23 p40 levels.
CSF IL-12/23 p40 according to clinical diagnosis
In the additional analyses, the patient group was divided according to the clinical diagnoses
(Table 2). The patients and healthy controls were comparable in terms of age, gender, BMI,
Table 1. Serum and CSF levels of cytokines and chemokines (pg/mL) in 52 patients with cognitive








IL-6 0.88 (0.81–1.54) 1.04 (0.84–1.78) 0.19
IL-8 15.0 (10.8–18.9) 14.4 (11.6–19.2) 0.91
IL-12/23 p40 117 (79–157) 143 (102–185) 0.12
IL-15 2.00 (1.74–2.34) 1.91 (1.54–2.13) 0.23
IL-16 249 (195–328) 345 (289–482) 0.0044
VEGF-A 162 (103–246) 171 (109–254) 0.97
IP-10 252 (193–359) 293 (234–461) 0.23
MCP-1 310 (250–400) 412 (319–477) 0.03
MIP-1β 135 (108–158) 112 (85–184) 0.59
CSF values
IL-6 1.14 (0.78–1.47) 1.18 (0.96–1.62) 0.29
IL-8 51.5 (41.0–64.4) 55.4 (43.9–66.9) 0.59
IL-12/23 p40 3.58 (3.01–4.60) 4.73 (4.08–6.29) 0.0020
IL-15 3.19 (2.76–3.92) 3.51 (3.04–4.12) 0.28
IL-16 7.59 (5.97–9.52) 8.50 (6.83–8.88) 0.35
VEGF-A 4.87 (4.17–5.48) 4.71 (4.56–5.01) 0.89
IP-10 539 (410–806) 631 (402–769) 0.97
MCP-1 514 (435–625) 450 (375–547) 0.11
MIP-1β 11.9 (10.4–13.6) 10.3 (9.2–13.5) 0.32
The unit is pg/mL for all variables. Values are given as the median (25th-75th percentile). P-values in the
right column were calculated using the Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0176760.t001
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and waist: hip ratio. AD biomarkers in CSF have been reported previously [17]. None of the
investigated variables in serum or CSF correlated with age or CSF/serum albumin ratio (data
not shown).
Serum IL-12/23 p40 did not differ between the study groups (Fig 1A) whereas CSF IL-12/
23 p40 was decreased in all patient subgroups (AD, other dementia, and SMCI) compared to
the controls (p< 0.01, p< 0.05, and p< 0.05, respectively; Fig 1B). The ratio between CSF
and serum values of IL-12/23 p40 did not differ between groups (Fig 1C).
Correlation analysis
We evaluated whether CSF IL-12/23 p40 correlated with CSF AD biomarkers and MMSE
score. In the total study population (n = 70), CSF IL-12/23 p40 concentrations correlated posi-
tively with CSF concentrations of Aβ1–42 (r = 0.24, p< 0.05) and P-tau (r = 0.25, p < 0.05;
Fig 2A) but not with CSF T-tau (r = 0.06) or MMSE score (r = 0.04). In AD patients (n = 30),
CSF IL-12/23 p40 correlated positively with CSF P-tau (r = 0.46, p = 0.01; Fig 2B) but not with
Aβ1–42 (r = 0.04), T-tau (r = 0.27), or MMSE score (r = -0.23).
Discussion
In this mono-center study, strictly defined procedures were followed in terms of clinical assess-
ments and diagnostic procedures including lumbar puncture [17]. The patients and controls
were matched in terms of age, gender, BMI, and waist: hip ratio [17]. None of the participants
had diabetes mellitus or received medical treatment with glucocorticoids, NSAIDs, or acetyl-
choline esterase inhibitors. The latter medication may be a confounder in studies of AD as
acetylcholine may modulate inflammatory responses [26]. Thus, several factors that could
influence cytokine concentrations were highly standardized. A limitation of the present study
is the cross-sectional design, and changes over time could therefore not be studied.
After corrections for multiple comparisons, serum as well as CSF concentrations of the
cytokines IL-6, IL-8, IL-15, IL-16, and the cytokine/growth factor VEGF-A were not











Men/women 15/15 9/2 5/6 10/8 0.27
Age (years) 74 (71–77) 74 (72–76) 72 (69–73) 76 (71–78) 0.26
BMI (kg/m2) 22.8 (21.7–25.1) 22.8 (20.4–25.3) 24.1 (23.2–26.2) 23.7 (22.7–25.2) 0.22
Waist/hip ratio 0.86 (0.78–0.91) 0.90 (0.88–0.93) 0.85 (0.79–0.90) 0.87 (0.83–0.91) 0.17
MMSE score 23 (19–25)a,b 22 (19–24)b,c 28 (27–29) 29 (27–29) < 0.0001
CSF Aβ1–42 (pg/mL) 409 (329–486)a,b 390 (337–507)c,d 671 (548–883)e 990 (786–1044) < 0.0001
CSF T-tau (pg/mL) 584 (413–782)a,b,f 311 (254–374) 270 (211–398) 327 (224–390) < 0.0001
CSF P-tau (pg/mL) 104 (78–116)b,c,f 46 (34–61)e 60 (37–79) 66 (56–80) < 0.0001
Values are given as the median (25th-75th percentile). The P-values in the right column refers to differences between all four groups using the Kruskal-
Wallis test. Comparisons between two separate groups were performed using the Mann-Whitney U test.
a p < 0.0001 vs. controls
b p < 0.001 vs. SMCI
c p < 0.001 vs. controls
d p < 0.05 vs. SMCI
e p < 0.05 vs. controls
f p < 0.0001 vs. other dementias.
https://doi.org/10.1371/journal.pone.0176760.t002
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significantly altered in the total patient group (n = 52) compared to the control group (n = 18).
Several studies including a meta-analysis have shown increased serum IL-6 concentration in
AD patients [12, 27, 28], whereas most [12, 29] but not all [30] studies have shown unchanged
Fig 1. Reduced CSF IL-12/23 p40 concentration in patients with cognitive impairment. (A) Serum IL-12/23 p40 concentration, (B) CSF IL-12/23 p40
concentration, and (C) CSF/serum IL-12/23 p40 ratio in the study population of AD patients (n = 30), other dementias (n = 11), SMCI (n = 11), and healthy
controls (n = 18). Values in the box plots are given as medians (horizontal lines), 25th-75th percentiles (boxes), and 10th-90th percentiles (whiskers).
Differences between multiple groups were assessed using the Kruskal-Wallis test, followed by the Mann-Whitney U test for pair-wise comparisons. *
p < 0.05, ** p < 0.01 vs. control group.
https://doi.org/10.1371/journal.pone.0176760.g001
Fig 2. CSF IL-12/23 p40 correlates positively with the CSF AD biomarker phosphorylated tau protein (P-tau). (A) In the total study population
(n = 70; r = 0.25, p < 0.05) as well as (B) in the AD group (n = 30; r = 0.46, p = 0.01), CSF IL-12/23 p40 concentration correlated positively with CSF P-tau
concentration. Note the logarithmic scale on both the x-axis and the y-axis. Correlations were sought using the Spearman rank order correlation test.
https://doi.org/10.1371/journal.pone.0176760.g002
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CSF IL-6 concentration in AD or VaD. Moreover, circulating or CSF concentrations of IL-8,
IL-15, IL-16, and VEGF have been decreased [31, 32], unchanged [12, 33–35], or increased
[34, 36–39] in AD. These relatively variable results in AD and VaD could, at least partly, be
explained by the fact that quantification of low cytokine levels in CSF is technically difficult.
However, we used highly standardized procedures to reduce measurements errors. Serum and
CSF samples had previously not been thawed, and the analyses were performed by experienced
laboratory technicians blinded to all clinical information.
In line with the results of other studies, we observed that concentrations of the chemokines
IP-10 and MCP-1 were higher in CSF than in serum in both controls and patients [37, 40].
However, serum as well as CSF concentrations of IP-10, MIP-1β, and MCP-1 were similar in
the total patient group compared to the control group after adjustment for multiple compari-
sons. In previous studies, unchanged [40, 41] or increased [37, 42] levels of IP-10 and MCP-1
have been found in blood or CSF of AD patients. Immunohistochemistry revealed elevated IP-
10 that co-localized with MIP-1β in astrocytes in AD brains, and IP-10 positive astrocytes were
associated with senile plaques [43]. Therefore, the expression of some chemokines might be
upregulated in astrocytes in the AD brain, but our results do not suggest that this is associated
with any major changes in their CSF concentrations.
CSF IL12/23 p40 concentration was reduced in the total patient group (n = 52) compared
to the control group (n = 18), and this difference remained also after correction for multiple
comparisons. IL-12 is a heterodimeric cytokine formed by a 35 kDa light chain (the p35 sub-
unit encoded by IL12A) and a 40 kDa heavy chain (the p40 subunit encoded by IL12B) [44].
The p40 subunit of IL-12 is shared with IL-23 [44, 45]. Both IL-12 and IL-23 has been impli-
cated in bacterial infections and autoimmune diseases [44, 45]. Furthermore, single nucleotide
polymorphisms (SNPs) in IL-12A (rs2243115 and rs568408) [46], IL-12B (rs3212227) [46], and
IL-23 receptor gene (rs10889677 and rs1884444) [47] were associated with the risk of AD in a
Chinese population, suggesting that the genes encoding IL-12 and IL-23 receptor could be risk
factors for late-onset AD susceptibility [46, 47].
We divided the total patient group according to the clinical diagnoses, and observed that
CSF IL12/23 p40 concentration was reduced in AD, other dementia, as well as SMCI com-
pared to the healthy controls. As the number of patients with other dementia or SMCI was rel-
atively low, we focused on the AD group (n = 30). A previous study in AD patients showed
unchanged serum and CSF concentrations of IL-12/23 p40 [48], and CSF IL-12 concentration
was unchanged [49] or reduced [50] in AD. However, our study included AD patients in rela-
tively early phases of the disease (median MMSE score = 23), whereas the previous studies
were performed in more advanced AD (mean MMSE scores between 16 and 18) [48–50].
In AD, MMSE score correlated negatively with CSF IL-12/23 p40 in one study [5], and CSF
IL-12 correlated positively with CSF tau levels in another study [50]. We did not observe any
correlation between CSF IL-12/23 p40 and MMSE score, but CSF IL-12/23 p40 correlated pos-
itively with CSF Aβ1–42 in the total study population (n = 70), and with CSF P-tau both in the
total population (n = 70) and in AD patients (n = 30). These findings might suggest that there
is an association between CSF IL-12/23 p40 concentration and markers of AD disease status.
However, although CSF IL-12/23 p40 was reduced and CSF P-tau was increased in AD
patients, the correlation between these analytes was positive. Therefore, the physiological
importance of this correlation is not fully clear and needs to be explored in further studies.
In a previous study, CSF concentrations of Aβ1–42 as well as the pro-inflammatory protein
S100A9 (MRP14) were decreased in AD patients and in the post-mortem brain, immunohisto-
chemical analyses showed intense co-localized immunostaining of S100A9 and Aβ [51]. This
possibly suggests that S100A9, like Aβ1–42, could be low in CSF of AD patients due to increased
aggregation/sequestration of S100A9 in the AD brain. Furthermore, the production of IL-12/
CSF IL-12/23 p40 in cognitive impairment
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23 p40 by microglia was increased in the APPPS1 mouse model of AD, and peripheral admin-
istration of a neutralizing p40-specific antibody reduced cerebral amyloid load [5]. Moreover,
using the senescence-accelerated mouse prone-8 (SAMP8) model, the expression of IL-12 and
IL-23 in the brain were upregulated during aging, and knock down of the p40 subunit by in
vivo infusion of interfering RNA decreased cerebral Aβ levels, reduced neuronal loss, and
reversed cognitive impairment [6]. IL-12/23 p40 has therefore been shown to be of pathophysi-
ological importance in animal studies of AD and it could be speculated that IL-12/23 p40, like
Aβ1–42 and S100A9, could be low in CSF due to increased aggregation/sequestration of IL-12/
23 p40 around AD plaques.
CSF IL-12/23 p40 was low also in patients with other dementias and SMCI. Few previous
studies have analyzed IL-12/23 p40 or IL-12 concentrations in dementias other than AD.
Serum and CSF IL-12/23 p40 were unchanged in VaD [48]. Nonamnestic multiple domain
MCI was associated with higher serum IL-12 concentration [52], whereas patients with fronto-
temporal dementia had reduced CSF IL-12 compared to patients with non-inflammatory neu-
rological diseases [50]. In our study, there were relatively few SMCI patients and the number
of each specific diagnosis was low in the other dementia group. Therefore, the role of IL-12/23
p40 in cognitive disorders other than AD needs to be explored in further studies.
Conclusions
In a homogenous, well-controlled study cohort, most of the cytokines and chemokines studied
were similar in patients and controls after correction for multiple comparisons. CSF IL-12/23
p40 concentration was decreased in AD patients and correlated with markers of AD disease
status. Based on previous animal data, it could be speculated that the reduced CSF IL-12/23
p40 concentration is secondary to aggregation/sequestration of IL-12/23 p40 around AD pla-
ques. Furthermore, CSF IL-12/23 p40 was decreased also in other dementias or SMCI, but the
number of patients in these groups was relatively small. Therefore, further studies are needed
to clarify the role of CSF IL-12/23 p40 in dementing disorders other than AD.
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